Month 6 on Semaglutide: The Halfway Mark of a Year
Twenty-six weeks of injections. Three full titrations behind you. Month 6 is the halfway point of a full treatment year and the place where most clinical trials measure their primary endpoints. The trajectory is no longer a guess.
By month 6, most users on the standard Wegovy titration are at either 1.7mg or 2.4mg, depending on tolerability and pace. The schedule reaches 2.4mg around week 17 if every step is taken on the four-week cadence, but many people hold longer at lower doses and arrive at 2.4mg a few weeks later. Both paths are routine.
The STEP 1 trial weight-loss curve shows mean cumulative loss of roughly 10% of starting body weight at the 6-month mark in the semaglutide arm. The curve is still descending — most users have not yet hit their plateau — but the steepest portion of the slope is behind them. Month 6 is where you can usually see the shape of where the line is heading.
Appetite Suppression
Deep, consistent suppression at 1.7mg or 2.4mg. Some users notice the slightest hunger return in the day or two before the next injection.
Mean cumulative loss at month 6 in STEP 1 was around 10%, with wide individual variation. Higher responders cluster well above; slower responders trend below.
The Month 6 journey
The Month 6 Timeline
Weeks 21-22
Settled at Therapeutic Dose
Whether you are at 1.7mg or 2.4mg, the symptom profile is usually well understood by now. New side effects this late are uncommon and worth a conversation with your prescriber.
Weeks 23-24
Six-Month Review
Repeat labs are commonly scheduled here — A1C, lipids, liver enzymes, basic metabolic panel. Many prescribers also check in on mood, sleep, and habit sustainability.
End of Month 6
Trajectory Set
The first plateau of the journey often shows up around now. A two- or three-week stall is normal and does not mean the medication has stopped working.
What changes by Month 6
The body has reorganized around the new pattern. Smaller portions feel normal; large meals feel actively uncomfortable. Restaurant servings often look comically oversized. Many users report a stable energy curve through the week rather than the post-injection dip that was common in early months.
Six months is also when the conversation usually starts to shift from weight loss to maintenance planning. Even if the goal weight is not in sight, the prescriber begins thinking about the long arc — what dose you settle at, what the eventual taper or hold looks like, and whether anything in the medication landscape has changed enough to warrant a switch.
The first real plateau usually appears in this window. A stretch of two to four weeks where the scale will not move, even though intake and routine are unchanged, is a normal feature of the loss curve, not a failure of the medication. Most people pass through it without intervention. If a plateau extends beyond four weeks at the same dose, that is when a dose review or a habit audit makes sense.
Navigating Symptoms
Side effects at month 6 are usually well-controlled. Sustained low energy, hair shedding, or new mood changes are worth flagging — they can be addressed without stopping the medication in most cases.
What other users say
What Users Report
“Six months, down 11%. I had a three-week stall around week 22 that freaked me out, then it started moving again on its own. Glad I did not panic.”
— Priya N.
“I'm at 1.7mg and my doctor and I agreed not to go to 2.4mg for now. The current dose is working and we want to leave room for later if I need it.”
— Marcus T.
Looking ahead
The second half of the year is where the curve flattens and the work becomes about consistency rather than progress. Continue to the Month 9 guide for what the approach to maintenance looks like, or revisit the resources hub for the broader picture.